QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic Diseases

Tuesday, October 10, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

Aiding the analysis of hereditary disorders by integrating genomic and clinical databases

HILDEN and ROSTOCK, Germany and GERMANTOWN, Maryland,

October 9, 2017 /PRNewswire/ --

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG today announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing insights into the complex interaction between genetics, biochemistry and clinical phenotypes of patients with hereditary disorders. More than 4,000 known genetic disorders are estimated to affect roughly 1 in 10 individuals.

Click here for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/2017-10-09-Centogene?sc_lang=en

Contacts: QIAGEN Public Relations Dr. Thomas Theuringer e-mail: [email protected] +49-2103-29-11826

Investor Relations John Gilardi e-mail: [email protected] +49-2103-29-11711

CENTOGENE CEO´s office Doreen Niemann e-mail: [email protected] +49-381-203-652-181

SOURCE Qiagen N.V.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook